Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026
Capital expenditures dips below year-ago levels
Q3 FY2026 capital expenditures of $83K (cash outflow) fell 16.2% year over year, behind the +33.5% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at +371.0% a year.
Context
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -16.2% toward the trailing-twelve-month pace of +33.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (209K) USD
- Year-over-year change
- -10.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (209K) | -10.6% |
| FY2024 | 2024-12-31 | (189K) | — |
| FY2022 | 2022-12-31 | (2K) | +95.3% |
| FY2021 | 2021-12-31 | (43K) | -126.3% |
| FY2020 | 2020-12-31 | (19K) | — |
Capital Expenditures vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 capital expenditures of $219K is the 6th largest of the 10 companies compared; the peer median is $334K.
- Its year-over-year change of +33.5% is the 3rd highest of 10, against a peer median of -42.1%.
- Over three fiscal years its annual growth of +371.0% compares with a peer median of -40.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.47M | -62.7% | -58.3% | 2.4% | |
| FY2025 | $2.31M | +30.5% | — | 171.3% | |
| FY2025 | $434K | -42.1% | -53.4% | 678.1% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $401K | -77.7% | -35.3% | 5.4% |
| LTM Jun 2026 | $334K | +165.1% | +15.3% | 17.5% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $219K | +33.5% | +371.0% | — |
| LTM Mar 2026 | $81K | -99.8% | -43.2% | 1.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77K | -34.2% | -78.9% | — |
| LTM Mar 2026 | $69K | -81.1% | -37.6% | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | +29.8% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | $334K | -42.1% | -40.4% | 5.4% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Dec 2020 | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.74M) | (19.32M) | (9.93M) | (83.72M) | (105.43M) |
| Depreciation & Amortization | 93K | 91K | 114K | 27K | 83K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.88M | (28K) | (1.66M) | 11.59M | (2.56M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.1M | (411K) | (783K) | 3.46M | 693K |
| Other Working Capital | 776K | 383K | (878K) | 8.13M | (3.25M) |
| Other Non-Cash Items | 43K | 497K | 561K | 14.27M | 19.7M |
| Operating Cash Flow | (7.73M) | (18.76M) | (10.91M) | (57.84M) | (88.21M) |
| Capital Expenditures | (19K) | (43K) | (2K) | (189K) | (209K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (329.94M) | (520.96M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 424.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (19K) | (43K) | (2K) | (330.13M) | (96.75M) |
| Debt Repayment | (408K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 48.86M | 23.09M | 0 | 449.54M | 170.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 48.45M | 23.09M | 0 | 449.54M | 170.32M |
| Effect of Forex Changes | 0 | 0 | 0 | (37.43M) | 0 |
| Net Change in Cash | 40.71M | 4.29M | (10.91M) | 24.14M | (14.64M) |
| Free Cash Flow | (7.74M) | (18.81M) | (10.91M) | (58.03M) | (88.42M) |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.